


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (Currently amended) A combined preparation for simultaneous, separate, or sequential administration in the treatment of cancer, comprising two separate preparations:

(a) a first preparation comprising, in combination with a pharmaceutically acceptable carrier or diluent, a compound of formula IA:



or a pharmaceutically acceptable salt thereof; and

(b) a second preparation comprising, in combination with a pharmaceutically acceptable carrier or diluent, at least one antitumor agent selected from the group consisting of 5-fluorouracil, doxorubicin, etoposide, ~~cisplatin, carboplatin,~~ irinotecan, topotecan, and camptothecin, or a pharmaceutically acceptable salt thereof, wherein, if said preparation contains

5-fluorouracil, it may further contain leucovorin or may be combined with a separate leucovorin preparation).

Claim 2. (Previously Cancelled).

Claim 3. (Previously Cancelled).

Claim 4. (Previously Cancelled).

Claim 5. (Previously Cancelled).

Claim 6. (Previously Cancelled).

Claim 7. (Previously Cancelled).

Claim 8. (Previously Cancelled).

Claim 9. (Previously Cancelled).

Claim 10. (Previously Cancelled).


Claim 11. (Previously amended) The combined preparation as claimed in Claim 1, wherein one of or both of the two separate preparations is/are parenteral preparation(s).

Claim 12. (Previously amended) The combined preparation as claimed in Claim 11, wherein one of or both of the two separate preparations is/are an injection or an infusion.

Claim 13. (Previously Cancelled).

Claim 14. (Currently amended) A method for cancer treatment, comprising simultaneously, separately or sequentially administering to a cancer patient:

(a) a therapeutically effective amount of a compound of formula IA:



or a pharmaceutically acceptable salt thereof;
and

(b) a therapeutically effective amount of at least one antitumor agent selected from the group consisting of 5-fluorouracil, doxorubicin, etoposide, ~~cisplatin~~, ~~carboplatin~~, irinotecan, topotecan, and camptothecin, or a pharmaceutically acceptable salt thereof (wherein, if the compound of formula IA is combined with 5-fluorouracil, leucovorin may be further combined).

Claim 15. (Previously Cancelled).

Claim 16. (Previously Cancelled).

Claim 17. (Previously Cancelled).

Claim 18. (Previously Cancelled).

Claim 19. (Previously Cancelled).

Claim 20. (Previously Cancelled).
Claim 21. (Previously Cancelled).
Claim 22. (Previously Cancelled).
Claim 23. (Previously Cancelled).
Claim 24. (Previously Cancelled).
Claim 25. (Previously Cancelled).
Claim 26. (Previously Cancelled).
Claim 27. (Previously Cancelled).
Claim 28. (Previously Cancelled).
Claim 29. (Previously Cancelled).
Claim 30. (Previously Cancelled).
Claim 31. (Previously Cancelled).
Claim 32. (Previously Cancelled).
Claim 33. (Previously Cancelled).

Claim 34. (Currently amended) A pharmaceutical composition comprising, in combination with a pharmaceutically acceptable carrier or diluent,

(a) a therapeutically effective amount of a compound of formula IA:

